Rochester, NY 7/16/2009 12:41:55 AM
PFE - Pfizer Alzheimer’s Drug Shows Perplexing Results in Mice Study
Pfizer Inc.
Pfizer Inc., PFE
WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
Pfizer Inc. and Medivation Inc.’s experimental Alzheimer’s therapy Dimebon, shown to reduce signs of memory loss in early studies, unexpectedly boosts levels of brain-clogging plaque associated with the disease’s development. The findings raise questions about the role of the amyloid protein that is the main component in the plaque that clogs the brains of Alzheimer’s patients, researchers said. Beta amyloid has long been considered a culprit in the development of the disease and is the target of numerous experimental drugs from companies including Elan Corp., Wyeth and Eli Lilly & Co.
About WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Sign up for our FREE alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
